NGL Fine-ChemNSE:NGLFINE -2.72%78 Operating Margin % is 10.96% as of Mar. 2026, which is 22% below its 10-year median of 13.97. GuruFocus rates NSE:NGLFINE with a GF Score™ of 78/100 and a GF Value™ of ₹2,803.99 (Fairly Valued). The stock has 8 warning signs investors should review. Among 955 Drug Manufacturers companies, NGL Fine-Chem ranks better than 56.54% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. NGL Fine-Chem's Operating Income for the
three
months ended in Mar. 2026 was ₹164 Mil. NGL Fine-Chem's Revenue for the
three
months ended in Mar. 2026 was ₹1,492 Mil. Therefore, NGL Fine-Chem's Operating Margin % for the quarter that ended in Mar. 2026 was 10.96%.
Warning Sign:
NGL Fine-Chem Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -21.1%.
The historical rank and industry rank for NGL Fine-Chem's Operating Margin % or its related term are showing as below:
NSE:NGLFINE'
s Operating Margin % Range Over the Past 10 Years
Min: 5.82 Med: 13.97 Max: 29.93
Current: 10.43
NSE:NGLFINE's Operating Margin % is ranked better than 56.54% of 955
companies
in the Drug Manufacturers industry
Industry Median: 7.45
vs NSE:NGLFINE: 10.43
NGL Fine-Chem's 5-Year Average Operating Margin % Growth Rate was -21.10% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
NGL Fine-Chem Operating Margin % Related Terms
NGL Fine-Chem Operating Margin % Historical Data
* Premium members only.
The historical data trend for NGL Fine-Chem's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NGLFINE vs LLY, JNJ, ABBV: Operating Margin % Comparison
For the Drug Manufacturers - General subindustry, NGL Fine-Chem's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NGL Fine-Chem Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NGL Fine-Chem's Operating Margin % distribution charts can be found below:
* The bar in red indicates where NGL Fine-Chem's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
NGL Fine-Chem's Operating Margin % for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NGL Fine-Chem (NSE:NGLFINE) has a Operating Margin % of 10.96% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on NGL Fine-Chem and its competitors. This is 22% below median its historical median of 13.97. Over the past decade, NGL Fine-Chem's Operating Margin % has ranged from 5.82 to 29.93. According to the industry distribution chart, NGL Fine-Chem ranks #415 out of 955 companies in the Drug Manufacturers industry, placing it in the top 43.5%.
Is NGL Fine-Chem's Operating Margin % too high?
NGL Fine-Chem's current Operating Margin % of 10.96% is 22% below median its 10-year median of 13.97. Over the past 10 years, this metric has ranged from a low of 5.82 to a high of 29.93. The Drug Manufacturers industry median Operating Margin % is 7.45. NGL Fine-Chem's value of 10.96% is 47.1% above this industry median. Based on the distribution chart, NGL Fine-Chem ranks #415 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, NGL Fine-Chem has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NGL Fine-Chem's Operating Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, NGL Fine-Chem ranks #415 out of 955 companies for Operating Margin %. This puts NGL Fine-Chem in the upper half of its industry. The industry median Operating Margin % is 7.45. NGL Fine-Chem's value of 10.96% is 47.1% above this benchmark. Historically, NGL Fine-Chem's own Operating Margin % has ranged from 5.82 to 29.93 over the past decade. While the company's 10-year median is 13.97 vs. the industry median of 7.45, NGL Fine-Chem has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NGL Fine-Chem's current Operating Margin % of 10.96% is 47.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on NGL Fine-Chem and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NGL Fine-Chem's current Operating Margin % is 10.96%, which is 22% below median its own 10-year median of 13.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NGL Fine-Chem stock overvalued right now?
Based on GuruFocus' analysis, NGL Fine-Chem (NSE:NGLFINE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,803.99, compared to a current price of ₹2,989.90 — trading 6.6% above its estimated fair value. The current Operating Margin % is 10.96%, which is 22% below median its 10-year median of 13.97 and 47.1% above the Drug Manufacturers industry median of 7.45. NGL Fine-Chem's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For NGL Fine-Chem (NSE:NGLFINE), the current Operating Margin % is 10.96% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NGL Fine-Chem (NSE:NGLFINE) Overvalued in 2026?
Based on GuruFocus' analysis, NGL Fine-Chem stock appears to be overvalued.
The current stock price of ₹2,989.90 is trading 6.6% above its estimated GF Value™ of ₹2,803.99.
GuruFocus considers NGL Fine-Chem to be Fairly Valued.
Key valuation signals for NSE:NGLFINE:
Operating Margin %: 10.96% (22% below median its 10-year median of 13.97)
GF Value™: ₹2,803.99 vs. price of ₹2,989.90 (6.6% above fair value)
Industry Position: 47.1% above the Drug Manufacturers median (#415 of 955)
No single metric tells the full story. See the NSE:NGLFINE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NGL Fine-Chem Ltd is an Indian company engaged in the pharmaceutical business. It is a manufacturer of pharmaceuticals and intermediates for use in veterinary and human health, catering to various companies to custom-manufacture pharmaceuticals. The company's product portfolio comprises animal health APIs such as homidium chloride, nitroxynil, clorsulon, decoquinate, fenbendazole, etc.; human health APIs such as nitazoxanide and atovaquone; drug intermediates and specialty chemicals; and finished dosage forms such as diminazene aceturate granules and homidium chloride tablets. Geographically, the group generates maximum revenue from the Asia-Pacific region, and the rest from India, Europe, the USA, and the rest of the world.
78GF Score
Get the complete analysis for NSE:NGLFINE
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NGLFINE has been successfully added to your 
